1Syrjanen S,Shabalova IP,Petrovichev N,et al Human papillomavirus testing and conventional Pap smear cytology as optional screening tools of women at different risks for cervical cancer in countries of the former Soviet Union.J low Genit Tract Dis,2002,6:97-110. 被引量：1
3Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000:the global picture[ J]. Eur J Cancer,2001,37 : S4-S66 被引量：1
4Munoz N, Bosch FX, De Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer[ J]. New Eng J Med,2003 ,348 :518-527 被引量：1
5Embers ME, Budgeon LR, Pickel M, et al. Protective immunity to rabbit oral and cutaneous papillomaviruses by immunization with short peptides of L2, the minor capsid protein [ J ]. Virol, 2002,76 : 9798 -9805 被引量：1
6Bermudez-Humaran LG, Cortes-Perez NG, LeLoir Y, et al.An inducible surface presentation system improves cellular immunity against human papillomavirus type 16 E7 antigen in mice after nasal administration with recombinant lactococci[ J ]. J Med Microbiol,2004 ,53 :427-433 被引量：1
7Devaraj K, Gillison ML. Development of HPV vaccines for HPV-associated head and neck squmaous cell carcinoma[ J ]. Crit Rev Oral Biol Med,2003 ,14 :345-362 被引量：1
8Nardelli-Haefliger D, Wirthner D, Schiller JT, et al. Specific antibody levels at the cervix during the menstrual cycle of women vaccined with human papillomavirus 16 viruslike particles[ J ]. Natl Cancer Inst,2003,95 : 1128-1137 被引量：1
9Mao C, Koutsky LA, Auh KA, et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial [ J ]. Obstet Gynecol,2006,107 : 18-27 被引量：1
10Steinbrook R. The potential of human papillomavirus vaccines [ J ]. New Eng J Med,2006,354 : 1109-1112 被引量：1
2Katesmark M, Coulter-Smith S, Reynolds K, et al. A pilot study of the efficacy and tolerability of intralesional recombinant human beta-interferons in eervical intraepithelial neoplasia [ J ]. Ann Acad Med Singapore, 1999,28 (6) :775-777. 被引量：1
3Ramos MC, Mardegan MC, Tirone NR, et al. The clinical use of type 1 interferon in gynecology [ J ]. Eur J Gynaecol Oncol,2010,31 ( 2 ) : 145-150. 被引量：1
4Sikorski M, Zrubek H. Recombinant human interferon gamma in the treatment of cervical intraepithelial neoplasia(CIN) associated with human papillomavirus (HPV) infection [ J ]. Eur J Gynaecol Oncol, 2003,24 ( 2 ) : 147- 150. 被引量：1
5Koromilas AE,Li S, Matlashewski G. Control of interferon signaling in human papillomavirus infection [ J].Cytokine Growth Factor Rev,2001,12(2-3 ) : 157-170. 被引量：1
6Iljazovic E, Ljuca D, Sahimpasic A, et al. Efficacy in treatment of cervical HRHPV infection by combination of beta interferon, and herbal therapy in woman with different cervical lesions [ J ]. Bosh J Basic Med Sci, 2006,6 (4) : 79- 84. 被引量：1
7Rotola A,Costa S, Di Luca D, et al. Beta-interferon treatment of cervical intraepithelial neoplasia: a multicenter clinical trial [ J ]. Intervirology, 1995,38 ( 6 ) :325-331. 被引量：1
8Belinson,SE.; Belinson,JL.Human Papillomavirus DNA Testing for Cervical Cancer Screening:Practical Aspects in Developing Countries[J].Molecular Diagnosis & Therapy.2010,14(4):215-222. 被引量：1
9Tarkkanen J,Auvinen E,Nieminen P,et al.HPV DNA testing as an adjunct in the management of patients with low grade cytological lesions in Finland[J].Acta Obstet Cynecol Scan,2007,86(3):367-372. 被引量：1
10Belinson SE, Belinson JL. Human papillomavims DNA testing for cervical cancer screening: practical aspects in developing countries [J]. Mol Diagn & Ther, 2010, 14(4) : 215-222. 被引量：1
